Apimeds to Consult FDA on Bee Venom Treatment for Osteoarthritis

The pharmaceutical partners intend to advance LT-100 by integrating historical clinical data with modern U.S. development standards. Originally developed and approved in South Korea, the treatment leverages purified honeybee venom to address the chronic pain and inflammation associated with osteoarthritis.

Refining the Clinical Approach

A central component of the new regulatory strategy involves optimizing the drug's delivery method. According to Erik Emerson, President of Apimeds and CEO of Lkahi Therapeutics, the companies are updating the route of administration to align with current clinical best practices. This shift is intended to enhance the treatment's therapeutic potential while reducing the logistical burden on both patients and healthcare providers.

By reconciling international results with domestic requirements, Apimeds and Lkahi aim to streamline the clinical trial process during the Type C meeting. The consultation will focus on these technical adjustments, positioning the program for continued progress toward U.S. regulatory approval.